SCHEMBL3683309

SCHEMBL3683309

CCCN(CCSc1ccc(OCC(=O)O)c(C)c1)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 14/20 0.45
PTGDR2 Q9Y5Y4 2/20 0.43
PTPN1 P18031 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
CA12 O43570 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
ABCC2 Q92887 1/20 0.42
SLC22A12 Q96S37 1/20 0.42
UGT1A7 Q9HAW7 1/20 0.42
SLC22A11 Q9NSA0 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3691055 0.97 PPARD (0.49) PPARDPTGDR2PTPN1MEN1LMNA
SCHEMBL3681848 0.92 KEAP1 (0.45) PPARDPTGDR2PTPN1CA2CA9
SCHEMBL3679328 0.91 PTGDR2 (0.44) PPARDPTGDR2PTPN1CA2CA9
SCHEMBL3691500 0.91 PPARD (0.49) PPARDPTGDR2PTPN1CA2CA9
SCHEMBL3690384 0.91 PTGDR2 (0.44) PPARDPTGDR2PTPN1
SCHEMBL3686523 0.90 PTPN1 (0.45) PPARDPTGDR2PTPN1CA2CA9
SCHEMBL3697015 0.90 PPARD (0.52) PPARDPTGDR2CA2CA9CA12
SCHEMBL3689567 0.90 PPARD (0.52) PPARDPTGDR2PTPN1CA2CA9
SCHEMBL3691579 0.90 PPARD (0.42) PPARDPTGDR2PTPN1CA2CA9
SCHEMBL3686905 0.90 PPARD (0.57) PPARDPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG PPARD 1/4885PTGDR2 328/4885PTPN1 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.